Echocardiography cardiac structure measurements of Fabry cohort
| Post-treatment | Baseline | Year 1 | Year 2 | Year 5 | Year 7 | Year 10 |
|---|---|---|---|---|---|---|
| LVMI (g/m2) | ||||||
| Non-CKD5 | 48.5±12.7 | 46.1±12.7 | 50.2±21.0 | 48.8±13.0 | 48.6±13.5 | 48.3±13.5* |
| CKD5 | 73.3±23.1 | 71.3±19.3 | 78.1±24.6 | 90.4±30.1 | 84.1±30.3 | 100.2±39.7 |
| IVSd (mm) | ||||||
| Non-CKD5 | 10.7±2.2 | 10.3±2.2 | 10.4±2.7 | 10.8±2.2 | 11.4±2.1 | 11.2±2.1* |
| CKD5 | 14.5±2.6 | 15.7±4.1 | 15.6±3.9 | 16.3±5.0 | 18.2±6.0 | 21.2±7.3 |
| PWd (mm) | ||||||
| Non-CKD5 | 10.6±1.9 | 10.2±1.9 | 10.5±2.6 | 10.8±2.3 | 10.9±2.4 | 10.4±2.6* |
| CKD5 | 13.8±3.2 | 13.9±3.6 | 13.0±3.5 | 15.0±2.5 | 14.7±2.1 | 15.4±3.9 |
| LVEDD (cm) | ||||||
| Non-CKD5 | 5.22±0.32 | 5.25±0.40 | 5.35±0.35 | 5.24±0.33 | 5.09±0.48 | 5.22±0.34 |
| CKD5 | 5.41±0.77 | 5.29±1.02 | 5.60±0.92 | 5.57±0.79 | 5.00±0.40 | 5.06±0.64 |
| LA (cm) | ||||||
| Non-CKD5 | 3.87±0.54 | 3.74±0.62 | 3.77±0.56 | 3.71±0.49 | 3.79±0.58 | 3.59±0.43 |
| CKD5 | 4.08±0.75 | 4.05±0.95 | 4.26±0.70 | 4.29±0.70 | 3.98±0.47 | 4.18±0.64 |
Non-CKD5 cohort size: baseline (N=15), year 1 (N=15), year 2 (N=15), year 5 (N=12), year 7 (N=12) and year 10 (N=12).
CKD5 cohort size: baseline (N=10), year 1 (N=9), year 2 (N=10), year 5 (N=7), year 7 (N=6) and year 10 (N=5).
Two-way ANOVA comparing non-CKD5 with CKD5 for parameters LVMI, IVSd, PWd and LA over the duration of treatment were statistically different (p<0.0001, p<0.0001, p<0.0001 and p=0.023, respectively) while LVEDD remained stable (p=0.37).
*LVMI, IVSd and PWd in non-CKD5 cohort showed no significant increase over 10 years (p=0.96, p=0.61, p=0.83, respectively).
ANOVA, analysis of variance; CKD5, chronic kidney disease stage 5; IVSd, inter-ventricular septal wall thickness; LA, left atrial diameter; LVEDD, LV end diastolic diameter; LVMI, LV mass index; PWd, posterior wall thickness.